2011 年 32 巻 Special_Issue_2 号 p. S195-S196
Model-Based drug development (MBDD) is not so widely used Japan relative to U. S. A and EU. This is because 1) not so many well educated pharmacometricians with enough skills exist in Japan, 2) necessary databases for MBDD are not well organized in Japan. These two deficiencies lead to the paucity of disease progression model for Japanese patients. Pharmacometricians including pahramacokineticists, biostatisticians, and clinical pharmacologists have to collaborate with each other to solve these problems and contribute to the public health of Japan by ensuring development of new effective and safe drug compounds.